Perceptive Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Perceptive Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-7,060	Closed	-$350K	–	209
2015 Q2	$350K	Buy	+7,060	New	+$422K	0.02%	136
2014 Q3	–	Sell	-22,400	Closed	-$1.38M	–	160
2014 Q2	$1.38M	Buy	+22,400	New	+$1.3M	0.14%	72

Other funds holding OREX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors's OREX Position: Q3 2015 in Review

Perceptive Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 7,060 shares — an estimated $350K sold.

Perceptive Advisors first reported a position in OREX in Q2 2014 and held it in 2 quarters. The position peaked at $1.38M in Q2 2014. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

Perceptive Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Perceptive Advisors sold 7,060 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $350K.
Perceptive Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
Perceptive Advisors's Orexigen Therapeutics, Inc. position peaked at $1.38M in Q2 2014.
132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.